Who can take part?

You may be eligible if you:

• Are aged 55–80

• Have a family member or friend who knows you well and can attend visits with you

• If you are aged 55-64 you must meet one of the following criteria:

  • First degree relative diagnosed with dementia onset before age 75,

  • Known to possess at least one APOE 4 allele, or

  • Evidence of brain amyloid pathology according to previous biomarker result

Approximately 100 participants will take part in the study in the UK and 1600 worldwide.

Who may not be eligible?

You may not be able to take part in this study if any of the following apply to you:

• You have been diagnosed with a condition affecting the brain or nervous system that may affect memory or thinking, such as Mild Cognitive Impairment (MCI), Alzheimer's disease, another form of dementia, a stroke, or certain blood vessel conditions affecting the brain.

• You have had a substance use disorder within the last 12 months.

• You have a current or previous diagnosis of cancer, unless it has been successfully treated and is considered cured. Examples of exceptions may include some skin cancers, cervical carcinoma in situ, or localised prostate cancer.

Please note: this is not a complete list of eligibility criteria. Additional inclusion and exclusion criteria will be assessed by the study team during screening.

What does the trial involve?

• Study medication given via infusion once per month for the first six months, and then once every 6 months for up to 4-6 years

• PET brain scan

• Blood tests, including one to check for a specific protein called pTau217

• Regular health monitoring and assessments

Key details

• Participants without diagnosed memory impairment

• Length of trial: If successfully screened, up to 4-6 years

• Visit frequency: 12 visits in the first year and 3-4 visits per year afterwards

• Trial type: Phase 3 clinical trial